Antiretroviral drug treatment of CNS HIV-1 infection

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 299-311

  Yilmaz, Aylin ^a   Price, Richard W ^b   Gisslén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral drugs; Cerebrospinal fluid; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME P450 3A; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; GLYCOPROTEIN P; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM INFECTION; COGNITION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DIFFUSION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRIAL TOXICITY; MOLECULAR WEIGHT; MONOTHERAPY; PH; PLASMA PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE DRUG DOSE; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ENCEPHALITIS, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84855826065     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr492     Document Type: Review

References (139)

1. Ho DD, Rota TR, Schooley RT et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985; 313: 1493-7.
2. Hagberg L, Malmvall BE, Svennerholm L et al. Guillain-Barre syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis 1986; 18: 591-2.
3. Portegies P, de Gans J, Lange JM et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989; 299: 819-21.
4. Brew BJ, Rosenblum M, Price RW. AIDS dementia complex and primary HIV brain infection. J Neuroimmunol 1988; 20: 133-40.
5. Lescure FX, Omland LH, Engsig FN et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 2011; 52: 235-43.
6. d'Arminio Monforte A, Cinque P, Mocroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320-8.
7. Giancola ML, Lorenzini P, Balestra P et al. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 41: 332-7.
8. Tozzi V, Balestra P, Bellagamba R et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007; 45: 174-82.
9. Robertson KR, Smurzynski M, Parsons TD et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: 1915-21.
10. Simioni S, Cavassini M, Annoni JM et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243-50.
11. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006; 66: 1447-50.
12. Heaton RK, Clifford DB, Franklin DR Jr et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 2087-96.
13. Edén A, Price RW, Spudich S et al. Immune activation of the central nervous system is still present after .4 years of effective highly active antiretroviral therapy. J Infect Dis 2007; 196: 1779-83.
14. Andersson LM, Hagberg L, Rosengren L et al. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia-case report. BMC Infect Dis 2006; 6: 141.
15. Engelhardt B, Sorokin L. The blood-brain and the blood- cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009; 31: 497-511.
16. Groothuis DR, Levy RM. The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 1997; 3: 387-400.
17. Haas DW, Johnson B, Nicotera J et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 2003; 47: 2131-7.
18. Best B, Letendre S, Croteau D et al. Therapeutic DRV and ETR concentrations in cerebrospinal fluid. In: Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011. Abstract 643. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
19. Enting RH, Hoetelmans RM, Lange JM et al. Antiretroviral drugs and the central nervous system. AIDS 1998; 12: 1941-55.
20. Haas DW, Clough LA, Johnson BW et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses 2000; 16: 1491-502.
21. Thomas SA, Segal MB. The transport of the anti-HIV drug, 2',3'-didehydro-3'-deoxythymidine (D4T), across the blood-brain barrier and blood-cerebrospinal fluid barriers. Br J Pharmacol 1998; 125: 49-54.
22. Soulas C, Conerly C, Kim WK et al. Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation. Am J Pathol 2011; 178: 2121-35.
23. Vernazza P, Daneel S, Schiffer V et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) trial. AIDS 2007; 21: 1309-15.
24. Gutmann C, Cusini A, Gunthard HF et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24: 2347-54.
25. Katlama C, Valantin MA, Algarte-Genin M et al. Efficacy of darunavir/ ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 2365-74.
26. Parkin NT, Hellmann NS, Whitcomb JM et al. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 437-43.
27. Acosta E, Limoli K, Trinh L et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. In: Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011. Abstract 633. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
28. Back D, Gatti G, Fletcher C et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 Suppl 1: S5-37.
29. Condra JH, Petropoulos CJ, Ziermann R et al. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis 2000; 182: 758-65.
30. Shaik N, Giri N, Pan G et al. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 2007; 35: 2076-85.
31. Djabarouti S, Breilh D, Pellegrin I et al. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study). J Antimicrob Chemother 2006; 58: 1090-3.
32. Almond LM, Edirisinghe D, Dalton M et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 2005; 78: 132-42.
33. Chaillou S, Durant J, Garraffo R et al. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials 2002; 3: 493-501.
34. Fayet-Mello A, Buclin T, Franc C et al. Intracellular and plasma pharmacokinetics of raltegravir in HIV-infected patients. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 133. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
35. Ho DD. Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo. J Clin Invest 1997; 99: 2565-7.
36. Takahashi K, Wesselingh SL, Griffin DE et al. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 1996; 39: 705-11.
37. Aquaro S, Perno CF, Balestra E et al. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol 1997; 62: 138-43.
38. Aquaro S, Calio R, Balzarini J et al. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002; 55: 209-25.
39. Takasawa K, Terasaki T, Suzuki H et al. Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J Pharmacol Exp Ther 1997; 282: 1509-17.
40. McDowell JA, Chittick GE, Ravitch JR et al. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43: 2855-61.
41. McDowell JA, Lou Y, Symonds WS et al. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44: 2061-7.
42. Capparelli EV, Letendre SL, Ellis RJ et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2005; 49: 2504-6.
43. Brew BJ, Halman M, Catalan J et al. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials 2007; 2: e13.
44. Antinori A, Perno CF, Giancola ML et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41: 1787-93.
45. Burger DM, Kraayeveld CL, Meenhorst PL et al. Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Pharm World Sci 1995; 17: 218-21.
46. Gisslén M, Norkrans G, Svennerholm B et al. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997; 175: 434-7.
47. Best B, Letendre S, Capparelli E et al. Efavirenz and emtricitabine concentrations consistently exceed wild-type IC50 in cerebrospinal fluid: CHARTER findings. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 702. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
48. Best BM, Letendre SL, Brigid E et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23: 83-7.
49. Foudraine NA, Hoetelmans RM, Lange JM et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351: 1547-51.
50. Blaschke A, Capparelli E, Ellis R et al. A population model-based approach for determining lamivudine (3TC) cerebrospinal fluid (CSF) penetration in HIV-infected adults. In: Abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000. Abstract 310. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
51. Haworth SJ, Christofalo B, Anderson RD et al. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 235-8.
52. Brady KA, Boston RC, Aldrich JL et al. Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus. Pharmacotherapy 2005; 25: 10-7.
53. Zhang L, Price R, Aweeka F et al. Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study. Eur J Pharm Sci 2001; 12: 377-85.
54. Best B, Letendre S, Koopmans P et al. Low tenofovir concentrations in cerebrospinal fluid. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 131. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
55. Burger DM, Kraaijeveld CL, Meenhorst PL et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7: 1581-7.
56. Lane HC, Falloon J, Walker RE et al. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial. Ann Intern Med 1989; 111: 41-50.
57. Elovaara I, Poutiainen E, Lahdevirta J et al. Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection. Arch Neurol 1994; 51: 943-50.
58. Balis FM, Pizzo PA, Eddy J et al. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 1989; 114: 880-4.
59. Hagberg L, Andersson M, Chiodi F et al. Effect of zidovudine on cerebrospinal fluid in patients with HIV infection and acute neurological disease. Scand J Infect Dis 1991; 23: 681-5.
60. Tozzi V, Narciso P, Galgani S et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993; 7: 683-92.
61. Sidtis JJ, Gatsonis C, Price RW et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 1993; 33: 343-9.
62. Tashima KT, Caliendo AM, Ahmad M et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999; 180: 862-4.
63. Best BM, Koopmans PP, Letendre SL et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 2010; 66: 354-7.
64. van Praag RM, van Weert EC, van Heeswijk RP et al. Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother 2002; 46: 896-9.
65. Veldkamp AI, Weverling GJ, Lange JM et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15: 1089-95.
66. Saitoh A, Sarles E, Capparelli E et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21: 2191-9.
67. Kim RB, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-94.
68. Kravcik S, Gallicano K, Roth V et al. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 1999; 21: 371-5.
69. Sadler BM, Chittick GE, Polk RE et al. Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. J Clin Pharmacol 2001; 41: 386-96.
70. Murphy R, Currier J, Gerber J et al. Antiviral activity and pharmacokinetics of amprenavir with or without zidovudine/3TC in the cerebrospinal fluid of HIV-infected adults. In: Abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2000. Abstract 314. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
71. Saumoy M, Tiraboschi J, Gutierrez M et al. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV Med 2011; 12: 438-41.
72. Yilmaz A, Izadkhashti A, Price RW et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009; 25: 457-61.
73. Arribas JR, Horban A, Gerstoft J et al. The MONET trial: darunavir/ ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. AIDS 2010; 24: 223-30.
74. Yilmaz A, Ståhle L, Hagberg L et al. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ ritonavir regimen. Scand J Infect Dis 2004; 36: 823-8.
75. Capparelli EV, Holland D, Okamoto C et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005; 19: 949-52.
76. DiCenzo R, DiFrancesco R, Cruttenden K et al. Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults. Ann Pharmacother 2009; 43: 1972-7.
77. Meynard JL, Bouteloup V, Landman R et al. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother 2010; 65: 2436-44.
78. Lafeuillade A, Solas C, Halfon P et al. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002; 3: 27-35.
79. Letendre SL, van den Brande G, Hermes A et al. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis 2007; 45: 1511-7.
80. Yilmaz A, Fuchs D, Hagberg L et al. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. BMC Infect Dis 2006; 6: 63.
81. Karlström O, Sta°hle L, Perrin L et al. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients. Scand J Infect Dis 2006; 38: 371-4.
82. Moyle GJ, Sadler M, Buss N. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy. Clin Infect Dis 1999; 28: 403-4.
83. Gisolf EH, Enting RH, Jurriaans S et al. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/ stavudine. AIDS 2000; 14: 1583-9.
84. Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-63.
85. Calcagno A, Bonora S, Bertucci R et al. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. AIDS 2010; 24: 931-2.
86. Yilmaz A, Gisslén M, Spudich S et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS ONE 2009; 4: e6877.
87. Croteau D, Letendre S, Best BM et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 2010; 54: 5156-60.
88. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003; 100: 10598-602.
89. Price RW, Parham R, Kroll JL et al. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 2008; 13: 369-74.
90. van Lelyveld SF, Nijhuis M, Baatz F et al. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis 2010; 50: 387-90.
91. Thomas SA. Drug transporters relevant to HIV therapy. J HIV Ther 2004; 9: 92-6.
92. Yilmaz A, Watson V, Else L et al. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009; 23: 2537-40.
93. Tiraboschi JM, Niubo J, Curto J et al. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J Acquir Immune Defic Syndr 2010; 55: 606-9.
94. European Public Assessment Report (EPAR). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000811/ human_med_000689.jsp&mid=WC0b01ac058001d124 (20 September 2011, date last accessed).
95. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
96. Letendre SL, Ellis RJ, Ances BM et al. Neurologic complications of HIV disease and their treatment. Top HIV Med 2010; 18: 45-55.
97. Tozzi V, Balestra P, Salvatori MF et al. Changes in cognition during antiretroviral therapy: comparision of two different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52: 56-63.
98. Tozzi V, Balestra P, Salvatori M et al. Changes in cognition during HAART: comparison of 2 different scoring systems to measure antiretroviral drug efficacy on HIV dementia. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 391. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
99. Eden A, Fuchs D, Hagberg L et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202: 1819-25.
100. Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 1359-66.
101. Hagberg L, Cinque P, Gisslén M et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010; 7: 15.
102. Staprans S, Marlowe N, Glidden D et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999; 13: 1051-61.
103. Ellis RJ, Gamst AC, Capparelli E et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000; 54: 927-36.
104. Cinque P, Presi S, Bestetti A et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retroviruses 2001; 17: 377-83.
105. Eggers C, Hertogs K, Sturenburg HJ et al. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003; 17: 1897-906.
106. Mellgren A, Antinori A, Cinque P et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005; 10: 701-7.
107. Gisslén M, Norkrans G, Svennerholm B et al. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir. AIDS 1998; 12: 114-6.
108. Spudich SS, Nilsson AC, Lollo ND et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5: 98.
109. Spudich S, Lollo N, Liegler T et al. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194: 1686-96.
110. Gisslén M, Svennerholm B, Norkrans G et al. Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens. Scand J Infect Dis 2000; 32: 365-9.
111. Gisslén M, Norkrans G, Svennerholm B et al. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997; 175: 434-7.
112. Yeh RF, Letendre S, Norak I et al. Single-agent therapy with lopinavir/ ritonavir controls HIV-1 viral replication in the central nervous system. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angels, CA, 2007. Abstract E-177. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
113. Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-99.
114. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10: 350-7.
115. Schouten J, Cinque P, Gisslén M et al. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011; 25: 561-75.
116. Tozzi V, Balestra P, Galgani S et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999; 13: 1889-97.
117. Robertson KR, Robertson WT, Ford S et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004; 36: 562-6.
118. Marra CM, Lockhart D, Zunt JR et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003; 60: 1388-90.
119. McCutchan JA, Wu JW, Robertson K et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 2007; 21: 1109-17.
120. Cysique LA, Vaida F, Letendre S et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73: 342-8.
121. Letendre SL, McCutchan JA, Childers ME et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56: 416-23.
122. Smurzynski M, Wu K, Letendre S et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25: 357-65.
123. Winston A, Duncombe C, Li PC et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50: 920-9.
124. Pilcher CD, Shugars DC, Fiscus SA et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 2001; 15: 837-45.
125. Ellis RJ, Hsia K, Spector SA et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42: 679-88.
126. Gisslén M, Hagberg L, Rosengren L et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmun Pharmacol 2007; 2: 112-9.
127. McArthur JC, McClernon DR, Cronin MF et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42: 689-98.
128. Gisslén M, Fuchs D, Svennerholm B et al. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999; 21: 271-6.
129. Harrington PR, Schnell G, Letendre SL et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS 2009; 23: 907-15.
130. Ritola K, Robertson K, Fiscus SA et al. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 2005; 79: 10830-4.
131. Schnell G, Spudich S, Harrington P et al. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009; 5: e1000395.
132. Sinclair E, Ronquillo R, Lollo N et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47: 544-52.
133. Canestri A, Lescure FX, Jaureguiberry S et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50: 773-8.
134. European AIDS Clinical Society (EACS). Guidelines for Treatment of HIV Infected Adults in Europe. www.europeanaidsclinicalsociety.org/ Guidelines/index.htm (20 September 2011, date last accessed).
135. Referensgruppen fö r AntiViral terapi (RAV). Treatment of HIV Infection: Swedish Recommendations. www.smittskyddsinstitutet.se/rav/ rekommendationer/hiv-virus/antiretroviral-behandling-av-hiv-infektion/ (20 September 2011, date last accessed).
136. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
137. Department of Health and Human Services. Adult and Adolescent Treatment Guidelines. www.aidsinfo.nih.gov/guidelines/GuidelineDetail. aspx?GuidelineID=7&ClassID=1 (15 November 2011, date last accessed).
138. de Almeida SM, Bhatt A, Riggs PK et al. Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. J Neurovirol 2010; 16: 6-12.
139. Bremell D, Säll C, Gisslén M et al. Lyme neuroborreliosis in HIV-1 positive patients successfully treated with oral doxycycline: case series and literature review. J Med Case Reports 2011; 5: 465.